Journal article
Reporting of Drug Reaction with Eosinophilia and Systemic Symptoms from 2002-2019 in the FDA Adverse Event Reporting System (FAERS)
The Journal of Allergy and Clinical Immunology: In Practice, Vol.9(8), pp.3208-3211.e1
2021
Abstract
Clinical Implications
• Of drug reaction with eosinophilia and systemic symptoms cases identified in the Food and Drug Administration Adverse Event Reporting System, five drugs account for more than 50% of cases and three have actionable HLA risk factors identifying implementation strategies for prevention and earlier diagnosis.
Details
- Title
- Reporting of Drug Reaction with Eosinophilia and Systemic Symptoms from 2002-2019 in the FDA Adverse Event Reporting System (FAERS)
- Authors/Creators
- S.B. Bluestein (Author/Creator) - Vanderbilt University Medical CenterR. Yu (Author/Creator) - Vanderbilt University Medical CenterC.A. Stone (Author/Creator)E.J. Phillips (Author/Creator) - Vanderbilt University Medical Center
- Publication Details
- The Journal of Allergy and Clinical Immunology: In Practice, Vol.9(8), pp.3208-3211.e1
- Publisher
- Elsevier
- Identifiers
- 991005541992507891
- Copyright
- © 2021 Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology
- Murdoch Affiliation
- Institute for Immunology and Infectious Diseases
- Language
- English
- Resource Type
- Journal article
UN Sustainable Development Goals (SDGs)
This output has contributed to the advancement of the following goals:
Source: InCites
Metrics
46 File views/ downloads
95 Record Views
InCites Highlights
These are selected metrics from InCites Benchmarking & Analytics tool, related to this output
- Collaboration types
- Domestic collaboration
- International collaboration
- Citation topics
- 1 Clinical & Life Sciences
- 1.265 Dermatology - Skin Allergies
- 1.265.1140 Drug Hypersensitivity
- Web Of Science research areas
- Allergy
- Immunology
- ESI research areas
- Clinical Medicine